Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
No treatment is best
Hundsberger T (2009). No treatment is best - Round table Low grade gliomas: Pros and cons. Präsentiert bei: 183. Annual meeting of the Swiss Neurology Society (SNG), -
15.12.2009No treatment is best
15.12.2009183. Annual meeting of the Swiss Neurology Society (SNG)
Hundsberger Thomas
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009; 32:724-30.
01.12.2009Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
01.12.2009Onkologie 2009; 32:724-30
Klaeser Bernd, Ruhstaller Thomas, von Moos Roger, Albrecht Susanne, Caspar Clemens, Pestalozzi Bernhard C, Zünd Michael, Brauchli Peter, Cescato-Wenger Corinne, Hany Thomas, Balmer-Majno Sabine, Widmer Lucas, Köberle Dieter, Schuller Jan C, Nitzsche Egbert, Lange Jochen
Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
Boehm S, Rothermundt C, Hess D, Jörger M. Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review. Gerontology 2009
26.11.2009Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
26.11.2009Gerontology 2009
Boehm S, Rothermundt Christian, Hess Dagmar, Jörger Markus
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V, Harter P. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2009; 21:370-5.
04.11.2009A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
04.11.2009Ann Oncol 2009; 21:370-5
du Bois A, Huober Jens, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V L, Harter P
Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines
Clerc J, Overkleeft H, Driessen C, Dudler R, Bachmann A, Huber R, Groll M, Kraus M, Florea B, Kaiser M. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem : a European journal of chemical biology 2009; 10:2638-43.
02.11.2009Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines
02.11.2009Chembiochem : a European journal of chemical biology 2009; 10:2638-43
Clerc Jérôme, Overkleeft Herman S, Driessen Christoph, Dudler Robert, Bachmann André S, Huber Robert, Groll Michael, Kraus Marianne, Florea Bogdan I, Kaiser Markus
Adjuvant! When the new world meets the old world
Huober J, Thürlimann B. Adjuvant! When the new world meets the old world. The Lancet 2009; 10:1028-9.
01.11.2009Adjuvant! When the new world meets the old world
01.11.2009The Lancet 2009; 10:1028-9
Huober Jens, Thürlimann Beat
Allerweltswort Spiritualität
Renz M. Allerweltswort Spiritualität. St. Galler Tagblatt 2009; 21. Okt.:2.
21.10.2009Allerweltswort Spiritualität
21.10.2009St. Galler Tagblatt 2009; 21. Okt.:2
Renz Monika
Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:
Cerny D, Cerny T, ess s, D'Addario G, Früh M. Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:. Onkologie 2009; 32:569-73.
13.10.2009Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:
13.10.2009Onkologie 2009; 32:569-73
Cerny David, Cerny Thomas, ess silvia, D'Addario G, Früh Martin
Primary manifestation of small lymphocytic lymphoma in the prostate
Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen Sommer S, Cathomas R. Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie 2009; 32:586-8.
01.10.2009Primary manifestation of small lymphocytic lymphoma in the prostate
01.10.2009Onkologie 2009; 32:586-8
Fehr Martin, Templeton Arnoud, Cogliatti Sergio B., Aebersold Franziska, Egli Fritz, Gillessen Sommer Silke, Cathomas Richard
Update of the BIG 1-98 Trial: where do we stand?
Jörger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand?. Breast 2009; 18 Suppl 3:S78-82.
01.10.2009Update of the BIG 1-98 Trial: where do we stand?
01.10.2009Breast 2009; 18 Suppl 3:S78-82
Jörger Markus, Thürlimann Beat
Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
von Moos R, Goldinger S, Michielin O, Schuller J, Gillessen Sommer S, Schlaeppi M, Cathomas R, Ochsenbein A, Seifert B, Dummer R (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). Präsentiert bei: ECCO / ESMO, Berlin
22.09.2009Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
22.09.2009ECCO / ESMO
von Moos Roger, Goldinger S., Michielin O., Schuller J.C., Gillessen Sommer Silke, Schlaeppi Marc, Cathomas R., Ochsenbein A., Seifert B., Dummer R.
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
12.09.2009Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
12.09.2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
Cathomas Richard, Köberle Dieter, Ruhstaller Thomas, Mayer Gisela, Räss Andrea, Mey Ulrich, von Moos Roger
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study
Langer I, Gueller U, Viehl C, Moch H, Wight E, Harder F, Oertli D, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009; 16:3366-74.
04.09.2009Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study
04.09.2009Ann Surg Oncol 2009; 16:3366-74
Langer Igor, Gueller Ulrich, Viehl Carsten T, Moch Holger, Wight Edward, Harder Felix, Oertli Daniel, Zuber Markus
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
Escudier B, Chen I, Maneval E, Flodgren P, Peschel C, Fountzilas G, Mulder S, Srinivas S, Harmenberg U, Gillessen Sommer S, Roigas J, Vogelzang N. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:4068-75.
01.09.2009Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
01.09.2009Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:4068-75
Escudier Bernard, Chen Isan, Maneval Edna Chow, Flodgren Per, Peschel Christian, Fountzilas George, Mulder Sasja F, Srinivas Sandhya, Harmenberg Ulrika, Gillessen Sommer Silke, Roigas Jan, Vogelzang Nicholas J
Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung
Omlin A, D'Addario G, Gillessen Sommer S, Cerny T, Vonhessling A, Früh M. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung cancer (Amsterdam, Netherlands) 2009; 65:383-4.
01.09.2009Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung
01.09.2009Lung cancer (Amsterdam, Netherlands) 2009; 65:383-4
Omlin Aurelius, D'Addario G, Gillessen Sommer Silke, Cerny Thomas, Vonhessling A, Früh Martin
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
Hitz F, Ghielmini M, Zimmermann D, Bertoni F, Cogliatti S, Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological oncology 2009; 27:154-9.
01.09.2009A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
01.09.2009Hematological oncology 2009; 27:154-9
Hitz Felicitas, Ghielmini M, Zimmermann D R, Bertoni F, Cogliatti Sergio B., Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.
01.09.2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
01.09.2009Ann Oncol 2009; 20:1489-98
Rabaglio M, Coates A S, Goldhirsch A, Gelber R D, Smith I, Láng I, Nogaret J-M, Pienkowski T, Colleoni M, Paridaens R J, Forbes J F, Campone M, Mouridsen H, Thürlimann Beat, Hawle H, Castiglione-Gertsch M, Price K N, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Pagani O, Goldhirsch A, Coates A, Fey M, Collins J, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Gelber R, Price K, International Breast Cancer Study Group (IBCSG). Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009; 117:319-24.
01.09.2009Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
01.09.2009Breast Cancer Res Treat 2009; 117:319-24
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Fey Martin F, Collins John, Thürlimann Beat, Lindtner Jurij, Holmberg Stig B, Castiglione-Gertsch Monica, Gelber Richard D, Price Karen N, International Breast Cancer Study Group (IBCSG)
Some comments to the Pattern of Care Study
Thürlimann B. Some comments to the Pattern of Care Study. Schweiz. Krebsbulletin 2009; 3:212-212.
01.09.2009Some comments to the Pattern of Care Study
01.09.2009Schweiz. Krebsbulletin 2009; 3:212-212
Thürlimann Beat
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8.
01.09.2009Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
01.09.2009Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8
Ruhstaller Thomas, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle Dieter, Balmermajno S, Pestalozzi B C, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J C, Widmer L, Swiss Group for Clinical Cancer Research (SAKK)